TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Superiority of Newly Developed Over Basic Echinacea Formulations for the Treatment of Respiratory Tract Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old~* Signed Informed Consent~Exclusion Criteria:~* Younger than 18 years~* Participation in another clinical study in the past 30 days~* Permanent intake of antimicrobial, antiviral, immune suppressive substances~* Surgical intervention in the 3 months prior to inclusion or planned surgery during period of observation~* Known diabetes melitus~* Known and treated atopy or asthma bronchiale~* Cystic fibrosis, bronchopulmonale dysplasia, COPD~* Known diseases of the immune system, degenerative illnesses (e.g. auto-immune disorders like AIDS or leukemia, myeloma)~* Known metabolic or resorptive disorders~* Known chronic liver diseases (chronic hepatitis, liver cirrhosis)~* Known chronic kidney insufficiency~* Serious health issues (reduced health status, autoimmune illness, tumorous illness)~* Known allergy to plants of compositae family (camomille, dandelion) or to any substances of the investigational product~* At inclusion known pregnancy or planned pregnancy during period of investigation (required: active contraception for women of childbearing year)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Formulation A (Type: EXPERIMENTAL): Echinacea purpurea alcoholic extract lozenges (novel formulation)
- Formulation B (Type: EXPERIMENTAL): Echinacea purpurea alcoholic extract spray (novel formulation)
- Formulation C (Type: ACTIVE_COMPARATOR): Echinacea purpurea alcoholic extract tablet (basic formulation, reference)
- Formulation D (Type: ACTIVE_COMPARATOR): Echinacea purpurea alcoholic extract, drops (basic formulation, reference)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
INCLUSION CRITERIA:~* Patients with alcohol-responsive Essential Tremor~* Limb involvement should be a prominent feature of the Essential tremor~* Patients must be willing and able to safely stop and remain off any medications used to treat essential tremor for at least 4 half-lives~* Patients must be willing to abstain from ethanol and caffeine intake for at least 48 hours prior to starting the study hospitalization until study termination~* Patients must be willing and able to fast for periods of up to 12 hours during the study~EXCLUSION CRITERIA:~* Patients with abnormalities other than tremor on neurological exam~* Patients with active or past alcohol abuse or dependence~* Patients with acute or chronic severe medical conditions such as renal failure, hepatic failure or lung disease~* Patients taking primidone~* Patients on other acute or chronic medications that influence hepatic metabolism or central nervous system (CNS) function and cannot be temporarily discontinued for the length of the study~* Patients who do not wish to take a potentially intoxicating drug~* Patients with abnormalities on their baseline screening laboratory tests~* Women who are pregnant or lactating~* Patients younger than age 21~* The presence of cognitive impairment preventing informed consent or cooperation during the study~* People of Far East Asian or Native American descent, who may possess variant alleles of the genes for alcohol metabolism, i.e., alcohol dehydrogenase and aldehyde dehydrogenase, resulting in altered (slower) metabolism and potentially increased sensitivity to alcohols and their metabolites

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Concentration of Ertapenem in Colorectal Tissue

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized patients 18 years or older requiring elective surgical intervention (open or laparoscopic surgery) at the colon will be eligible for this study.~* Patients with benignant disorders (e.g. colonic diverticulosis) will be preferred.~Exclusion Criteria:~* Pregnancy or lactation in women~* Emergency surgery, history of serious allergy or intolerance to β-lactam antibiotics and other carbapenems~* Systemic antimicrobial therapy with ceftazidime (internal standard of high-performance liquid chromatography / mass spectrometry) within a 7 days period prior to study entry~* Ongoing intraabdominal infections~* Terminal illness~* Chronic immunosuppressive therapy~* Severe diseases of the liver, e.g. cirrhosis of the liver with ALT or AST \> 6 x upper limit of normal (ULN) and bilirubin \> 3 x ULN, severe renal insufficiency with a creatinine clearance ≤30 mL/min., neutrophil count \< 1000 cells/mm3, platelets \< 75000 cells/mm3 and coagulation studies (INR) \> 1.5 x ULN, ongoing therapy with valproin acid.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Ertapenem (Type: EXPERIMENTAL): Administration of 1 gram ertapenem I.V.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Window to Hope-Evaluating a Psychological Treatment for Hopelessness Among Veterans With Traumatic Brain Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for Pilot Groups:~* Age between 18 and 89~* Determination of positive history of moderate/or severe TBI~* Ability to adequately respond to questions regarding the informed consent procedure~Exclusion Criteria for Pilot Groups:~* History of alcohol abuse in the seven days prior to baseline assessment~* History of non-alcohol substance abuse within the last 30 days prior to baseline assessment~* Same-day drug or alcohol abuse during treatment~* History of mild TBI only~* Inability to travel to the Denver VA for daily or weekly therapy sessions~Inclusion Criteria for RCT:~* Age between 18 and 65~* Determination of positive history of moderate/or severe TBI~* Beck Hopelessness Scale score of 9 or greater~* Ability to adequately respond to questions regarding the informed consent procedure~Exclusion Criteria for RCT:~* Diagnosis of neurological condition(s)~* History of alcohol abuse in the seven days prior to baseline assessment~* History of non-alcohol substance abuse within the last 30 days prior to baseline assessment~* Same-day drug or alcohol abuse during treatment~* History of mild TBI only~* Inability to travel to the Denver VA for weekly therapy sessions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- WtoH Intervention (Type: EXPERIMENTAL): Window to Hope: Psychotherapy consists of 10 2-hour sessions for a maximum dose delivered of 20 hours. Therapy consists of small groups of up to 2 participants.
- Waitlist Control (Type: OTHER): Members of the Waitlist Control arm continued to receive nonconstrained usual care from the Veterans Health Administration. Those initially allocated to the Waitlist Control arm were later provided with the opportunity to cross over and receive the WtoH Intervention after Time 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Atomoxetine in Veterans With Comorbid ADHD/PTSD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Veterans age 20 to 60 with PTSD and significant ADHD symptoms (CAARS-S:S \> 65);~* Good physical health.~* Evidence of combat as defined by:~  * Trauma exposure sufficient to meet Category A of PTSD criteria (Breslau and Kessler 2001)~Exclusion Criteria:~* Age younger than 20 or greater than 60.~* Known sensitivity to ATX~* Presence of disorders that could conceivable be exacerbated by atomoxetine (specifically, narrow angle closure glaucoma, urinary outflow obstruction, hypertension, and neurological disorders, particularly tics and Tourette's syndrome, or a history of epilepsy or seizures).~* Use of concomitant medication that could potentially interact with atomoxetine including monoamine oxidase inhibitors (MAOI), antihypertensive medication, or any concomitant medication that was a cytochrome 2D6 inhibitor (CYP2D6), since atomoxetine's elimination involves the CYP2D6 system.~* An active or lifetime major mental health diagnosis as determined by DSM-IV Axis I Disorders, including schizophrenia, schizoaffective disorder, psychotic disorder not otherwise specified, bipolar I disorder, bipolar II disorder, bipolar disorder not otherwise specified. The project will allow presence of depressive disorders if the depressive episodes are secondary to PTSD.~* Current substance dependence and abuse (within 3 month).~* Females who are pregnant.~* Suicidal thoughts and behavior. b. Sources of Material

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Atomoxetine 80mg (Type: ACTIVE_COMPARATOR): Atomoxetine (fixed dose of 80mg), a non-stimulant medication, FDA approve for treatment of ADHD. The active drug will be applied in first phase in group one and in second phase in group two
- Placebo (Type: PLACEBO_COMPARATOR): A pharmaceutically inert substance, which will be given to group one in their second phase and group tow in first phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia (0653-152)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients With A Diagnosis Of Primary Hypercholesterolemia And~* Who Are Defined As Being High Risk (10-Year Risk Of Coronary Artery Disease \> 20 % Based On The Framingham Model Or History Of Diabetes Mellitus Or Any Atherosclerosis Disease)~* And Have Not Reached Their Recommended Ldl-C Target Levels Of 2.5 Mmol/L While On A Statin Alone~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- group 1 (Type: EXPERIMENTAL): group 1: ezetimibe 10 mg per day is added to actual statin regimen for 6 weeks followed by an observational phase of 6 months.
- Group 2 (Type: ACTIVE_COMPARATOR): Group 2: patients on statins have their dose doubled for 6 weeks followed by another 6 month observational phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study for Recalcitrant Age Related Macular Degeneration

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide written informed consent and comply with study assessments for the full duration of the study~* Age \> 50 years~* Choroidal neovascularization secondary to AMD~* History of treatment with 0.5mg ranibizumab followed by 2.0mg ranibizumab for AMD~* Best corrected visual acuity in the study eye between 20/20 to 20/400 using an ETDRS chart~Exclusion Criteria:~* Pregnancy (positive pregnancy test) or lactation~* Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.~* Participation in another simultaneous medical investigation or trial~* Prior treatment with anti-VEGF therapy in the study eye within 28 days of baseline~* Prior treatment with PDT within the past 3 months or more than 4 prior PDT treatments.~* Presence of significant subfoveal fibrosis or atrophy.~* Prior treatment with intravitreal aflibercept injection~* Prior treatment with triamcinolone in the study eye within 6 months of BSL.~* Prior treatment with dexamethasone in the study eye within 30 days prior to BSL~* Intraocular surgery (including cataract surgery) in the study eye within 2 months preceding Baseline~* History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD in the study eye~* Active intraocular inflammation (grade trace or above) in the study eye~* Current vitreous hemorrhage in the study eye~* History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye~* Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye~* Uncontrolled glaucoma in the study eye (defined as IOP ≥ 30 mmHg despite treatment with anti-glaucoma medication)~* History of cerebral vascular accident, myocardial infarction, transient ischemic attacks within 3 months of study enrollment.~* History of allergy to fluorescein, ICG or iodine, not amenable to treatment~* History of retinal pigment epithelial tear or rip

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2.0 mg intravitreal Aflibercept (Type: OTHER): open label, Subjects seen monthly \& given mandatory 2.0 mg aflibercept at baseline, months 1, 2 and 4. Pro re nata (PRN) retreatment at months 3 and 5 was performed upon evidence of disease on spectral domain-optical coherence tomography (SD-OCT)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fathering In Recovery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion:~1. Father with at least part time custody of at least one child between the ages 3-12~2. In recovery from OUD~3. English-speaking~4. Abstinent from substances other than marijuana and alcohol for no more than 1 year~5. Has access to technology allowing for watching internet-based videos such as a smart phone or similar device. Participants will be screened for eligibility criteria by Influents Innovations staff.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FIR Prototype Evaluation (Type: EXPERIMENTAL): 30 fathers in recovery from opioid-use disorder will receive the prototype FIR online intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efavirenz to Nevirapine Switch and Low-Density Lipoprotein (LDL)-Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infected adults, who were receiving antiretroviral therapy including efavirenz for at least 6 months~* plasma HIV RNA\<400 cp/ml during the previous 4 months on 2 occasions 14 days apart~* Severe dyslipidemia with Low-Density Lipoprotein cholesterol (LDL-c) \>3.4 mmol/L in the presence of at least one of the 3 following coronary heart disease (CHD) risk factors: age\>45 among males or age\>55 among females, hypertension, current smoking, family history of CHD~* Low-Density Lipoprotein cholesterol (LDL-c)\>4.1 mmol/L regardless of CHD risk factors.~Exclusion Criteria:~* Protease inhibitors use within the previous 6 months,~* Prior exposure to nevirapine~* Asparate aminotransferase (AST) or alanine aminotransferase (ALT) \>2.5N if hepatitis virus B or C were negative~* AST or ALT\>1.25N if hepatitis virus B or C were positive~* Fasting glycemia\>1.26g/L,~* Current CHD~* Triglycerides\>4.6 mmol/L~* Introduction of lipid lowering drugs, corticoïds, retinoïds and betablockers within the previous 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 2 months (56 to 70 days) inclusive on the day of inclusion~* Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg~* Informed consent form signed by the parent(s) or other legal representative~* Able to attend all scheduled visits and to comply with all trial procedures~Exclusion Criteria:~* Participation in another clinical trial in the 4 weeks preceding the trial inclusion~* Planned participation in another clinical trial during the present trial period~* Congenital or acquired immunodeficiency, immunosuppressive therapy such as long term systemic corticosteroids therapy~* Systemic hypersensitivity to any of the vaccine components or history of a life threatening reaction to the trial vaccine or a vaccine containing the same substances~* Chronic illness at a stage that could interfere with trial conduct or completion~* Blood or blood derived products received in the past or current or planned administration during the trial (including immunoglobulins).~* Any vaccination in the 3 weeks preceding the first trial vaccination.~* History of diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b infection (confirmed either clinically, serologically or microbiologically).~* Clinical or known serological evidence of systemic illness including Hepatitis B, Hepatitis C and/or Human Immunodeficiency Virus (HIV) infection~* Previous vaccination against the diphtheria, tetanus, pertussis, poliomyelitis diseases or Haemophilus influenzae type b infection with the trial vaccine or another vaccine.~* Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination~* History of/current major neurological diseases or seizures.~* Febrile illness (axillary temperature ≥ 38ºC) or acute illness on the day of inclusion.~* Known family history of congenital or genetic immuno-deficiency.

- Gender: ALL
- Minimum Age: 56 Days
- Maximum Age: 70 Days
- Healthy Volunteers: t

Study Arms:
- Study Group A (Type: EXPERIMENTAL): Participants will receive a single dose of DTacP-IPV//PRP T combined vaccine (PENTAXIM™) at age 2, 4 and 6 months.
- Study Group B (Type: ACTIVE_COMPARATOR): Participants will receive a dose of DTacP IPV combined vaccine (TETRAXIM™) and PRP-T vaccine (ActHIB™) at 2, 4, and 6 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male participants~* Between the ages of 18 and 50~* Meet diagnostic criteria for schizophrenia or schizoaffective disorder~* Are clinically stable for a minimum of 3 months on current dose of medication~* Are unemployed (i.e., work less than 20 hours per week at competitive employment)~Exclusion Criteria:~* Psychoactive substance dependence within the past 6 months or substance abuse within the past month~* History of head trauma or other neurological disorder~* Medical illness or medications, such as benzodiazepine treatment or HIV medications, that may be affected by study participation (the study doctor will discuss this with potential subjects)~* Mental retardation~* Seizure disorder~* History of a heart attack, arrhythmia, or other heart disease

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Merck L-830982 (Type: EXPERIMENTAL): None
- Sugar pill (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Study of Efficacy of Intra-muscular Vitamin D3 in Tropical Calcific Pancreatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of tropical calcific pancreatitis established by history of abdominal pain or diabetes and evidence on ultrasound or CT scan of pancreatic ductal dilatation and intra-ductal stones~Exclusion Criteria:~* History of alcohol intake or any secondary cause for chronic pancreatitis (hypercalcemia, hypertriglyceridemia, biliary tract stones)~* History of hepatic or renal dysfunction or of current intake of drugs such as steroids, anticonvulsant drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: ACTIVE_COMPARATOR): IM Vitamin D3 3,00,000 Units single dose
- Group B (Type: ACTIVE_COMPARATOR): IM vitamin D3 6,00,000 Units single dose
- Group C (Type: ACTIVE_COMPARATOR): Oral vitamin D3 500 Units/ day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete